Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis - PubMed
4 hours ago
- #Cost-effectiveness analysis
- #Alzheimer's disease
- #Value-based pricing
- The study estimates value-based prices (VBPs) for Alzheimer's disease-modifying therapies lecanemab and donanemab across 174 countries using cost-effectiveness analysis.
- Compared to usual care, lecanemab and donanemab increased quality-adjusted life years (QALYs) by 0.38 and 0.51 on average, respectively.
- VBPs vary by country income level: for lecanemab, they range from $254 to $9,434 in high-income countries down to $4 to $18 in low-income countries.
- For donanemab, VBPs range from $387 to $13,964 in high-income countries to $9 to $32 in low-income countries.
- The framework provides guidance for countries on what to pay for these therapies and can be adapted for pricing negotiations.